别名 血红素氧化酶-1、bK286B10、heme oxygenase (decycling) 1 + [6] |
简介 Catalyzes the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron (PubMed:7703255, PubMed:11121422). Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolize free heme and prevent it from sensitizing cells to undergo apoptosis (PubMed:20055707).
(Microbial infection) During SARS-COV-2 infection, promotes SARS-CoV-2 ORF3A-mediated autophagy but is unlikely to be required for ORF3A-mediated induction of reticulophagy.
Catalyzes the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. |
作用机制 HMOX1调节剂 [+2] |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期1976-07-27 |
靶点 |
作用机制 HMOX1调节剂 |
在研机构 |
原研机构 |
非在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 HMOX1调节剂 |
最高研发阶段临床1/2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-10-30 |
申办/合作机构 |
开始日期2024-10-11 |
申办/合作机构- |
开始日期2024-10-01 |
申办/合作机构 |